美康生物
(300439)
| 流通市值：27.74亿 | | | 总市值：36.43亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 828,022,677.7 | 376,022,696.88 | 1,539,159,714.69 | 1,135,669,290.81 |
| 营业总成本 | 787,869,481.45 | 351,135,278.16 | 1,516,898,858.66 | 1,105,821,644.63 |
| 其他经营收益 | | | | |
| 营业利润 | 67,742,819.04 | 37,610,621.62 | 33,265,221.82 | 54,101,653.44 |
| 利润总额 | 66,438,388.21 | 36,976,398.24 | 46,092,646.26 | 53,406,580.01 |
| 净利润 | 61,555,662.61 | 33,187,998.12 | 61,361,976.78 | 58,893,569.05 |
| 每股收益 | | | | |
| 其他综合收益 | 1,251,247.48 | 737,416.79 | -628,731.08 | 1,261,533.54 |
| 综合收益总额 | 62,806,910.09 | 33,925,414.91 | 60,733,245.7 | 60,155,102.59 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,982,809,656.51 | 1,846,407,238.12 | 1,892,669,565.76 | 1,879,895,641.43 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,726,434,360.25 | 1,747,660,205.42 | 1,761,028,620.2 | 1,775,350,820.43 |
| 资产总计 | 3,709,244,016.76 | 3,594,067,443.54 | 3,653,698,185.96 | 3,655,246,461.86 |
| 流动负债: | | | | |
| 流动负债合计 | 640,483,180.56 | 534,005,769.7 | 623,985,598.16 | 602,922,198.57 |
| 非流动负债: | | | | |
| 非流动负债合计 | 71,402,847.62 | 78,902,660.27 | 82,078,989.14 | 103,836,229.57 |
| 负债合计 | 711,886,028.18 | 612,908,429.97 | 706,064,587.3 | 706,758,428.14 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,003,341,384.51 | 2,987,596,254.16 | 2,954,214,677.08 | 2,955,784,542.29 |
| 股东权益合计 | 2,997,357,988.58 | 2,981,159,013.57 | 2,947,633,598.66 | 2,948,488,033.72 |
| 负债和股东权益合计 | 3,709,244,016.76 | 3,594,067,443.54 | 3,653,698,185.96 | 3,655,246,461.86 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 917,110,209.52 | 401,149,719.09 | 1,567,591,925.06 | 1,395,144,984.04 |
| 经营活动现金流出小计 | 854,529,252.97 | 458,973,970.43 | 1,300,977,014.11 | 1,250,167,239.09 |
| 经营活动产生的现金流量净额 | 62,580,956.55 | -57,824,251.34 | 266,614,910.95 | 144,977,744.95 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 549,925,730.13 | 206,169,213.63 | 1,000,054,373.16 | 723,164,208.45 |
| 投资活动现金流出小计 | 722,384,160.35 | 213,945,535.89 | 1,258,407,877.19 | 873,382,080.85 |
| 投资活动产生的现金流量净额 | -172,458,430.22 | -7,776,322.26 | -258,353,504.03 | -150,217,872.4 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 60,000,000 | - | 37,538,668.06 | 2,694,000 |
| 筹资活动现金流出小计 | 37,067,135.08 | 20,085,510.47 | 114,251,446.15 | 93,191,945.04 |
| 筹资活动产生的现金流量净额 | 22,932,864.92 | -20,085,510.47 | -76,712,778.09 | -90,497,945.04 |
| 汇率变动对现金及现金等价物的影响 | -527,761.59 | -203,657.26 | -725,233.89 | -487,295.89 |
| 现金及现金等价物净增加额 | -87,472,370.34 | -85,889,741.33 | -69,176,605.06 | -96,225,368.38 |
| 期末现金及现金等价物余额 | 569,966,060.95 | 571,548,689.96 | 657,438,431.29 | 630,389,667.97 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -87,472,370.34 | - | -69,176,605.06 | - |